Tomohiro Oishi

Dr. Tomohiro Oishi

Kawasaki Medical School, Kurashiki, Japan
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Emerging Infectious Diseases
Verified
Journal Article
Open access
TTTakaaki Tanaka
Takaaki Tanaka
Tomohiro OishiTomohiro Oishi
Tomohiro Oishi
IMIppei Miyata
Ippei Miyata
SWShoko Wakabayashi
Shoko Wakabayashi
MKMina Kono
Mina Kono
KOKazunobu Ouchi
Kazunobu Ouchi
We evaluated isolates obtained from children with Mycoplasma pneumoniae infection throughout Japan during 2008–2015. The highest prevalence of macrolide-resistant M. pneumoniae was 81.6% in 2012, followed by 59.3% in 2014 and 43.6% in 2015. The prevalence of macrolide-resistant M. pneumoniae among children in Japan has decreased.

24 March 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Tomohiro OishiTomohiro Oishi
Tomohiro Oishi
Kazunobu OuchiKazunobu Ouchi
Kazunobu Ouchi
Among Mycoplasma pneumoniae (MP) is one of the major pathogens causing lower respiratory tract infection. Macrolide-resistant Mycoplasma pneumoniae (MRMP) isolates have been increasing and has become a global concern, especially in East Asian countries. This affects the treatment of MP infection; that is, some patients with MRMP infections fever cannot be controlled despite macrolide therapy. Therefore, alternative therapies, including secondary antimicrobials, including tetracyclines, fluoroquinolones, or systemic corticosteroids, were introduced. However, there are insufficient data on these alternative therapies. Thus, this article provides reviews of the recent trends in the epidemiology, diagnosis, and treatment of MRMP.

1 February 2021 in Journal of Infection and Chemotherapy
Verified
Journal Article
Open access
YNYoshitaka Nakamura
Yoshitaka Nakamura
Tomohiro OishiTomohiro Oishi
Tomohiro Oishi
KKKazunari Kaneko
Kazunari Kaneko
TKTsuyoshi Kenri
Tsuyoshi Kenri
TTTakaaki Tanaka
Takaaki Tanaka
Kazunobu OuchiKazunobu Ouchi
Kazunobu Ouchi
Mycoplasma pneumoniae contributes to numerous pneumonia cases among children and young adults. Therefore, this study aimed to investigate the prevalence of M. pneumoniae infections among Japanese children, occurring since 2008. Nasopharyngeal swab specimens were obtained from all cases, following which real-time PCR was performed to identify M. pneumoniae. Further, the p1 genotypes of isolates were determined using the PCR restriction fragment length polymorphism typing method. The annual rate of macrolide-resistant M. pneumoniae (MRMP) infections peaked at 81.8% in 2012 and decreased annually until 2015. Although the infection rate increased to 65.3% in 2016, it decreased again to 14.3% in 2018. Although >90% of isolates harbored the type 1 genotype until 2012, this rate decreased, and approximately 80% harbored p1 genotypes other than type 1 in 2018. Furthermore, the occurrence rate of MRMP among the type 1 isolates was very high (82.4%), whereas that among p1 genotypes other than type 1 was very low (6.5%). MRMP occurrence potentially decreased owing to changes in not only antibiotic usage but also in the distribution of p1 genotype among isolates.

25 September 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
Tomohiro OishiTomohiro Oishi
Tomohiro Oishi
TKTsuyoshi Kenri
Tsuyoshi Kenri
DYDaisuke Yoshioka
Daisuke Yoshioka
Mycoplasma pneumoniae (MP), an important pathogen that causes pneumonia among children and young adults, caused an epidemic every four years in Japan until 2016, with the next epidemic occurring eight years later in 2024. This study compared the prevalence of MP infections among Japanese children in 2024 to previous years using real-time polymerase chain reaction (PCR) and the p1 genotype determined using the PCR restriction fragment length polymorphism typing method from nasopharyngeal swab specimens. Of the 133 total isolates collected in 2024, 54.1% were macrolide-resistant MP (MRMP), with 98.0% of those containing an A2063G mutation in the 23S rRNA gene associated with macrolide resistance. This annual rate of MRMP and incidence of the A2063G mutation was similar to those in 2016. However, the dominant p1 genotype among isolates in 2024 was type 1 (93.4%), whereas type 2 was dominant in the previous epidemic. Thus, although the rate of MRMP in 2024 was similar to that in the previous epidemic year, the distribution of p1 genotypes was different. Further, the rate of MRMP was lower than neighboring Asian countries, including China and Korea, but was higher than in European countries. Therefore, it is important to continue monitoring MP infections in Japan.

21 January 2024 in Microorganisms
Verified
Journal Article
Open access
PDF file
Tomohiro OishiTomohiro Oishi
Tomohiro Oishi
NHNemu Hattori
Nemu Hattori
DYDaisuke Yoshioka
Daisuke Yoshioka
The rise of macrolide-resistant Mycoplasma pneumoniae (MRMP), marked by point mutations in the 23S rRNA gene, poses a growing global concern since its initial detection in 2001. The prominence of the A2063G mutation during this emergence remains unexplained. This study aimed to clarify the possibility of detecting MRMP from recent clinical macrolide-susceptible M. pneumoniae through exposure to azithromycin (AZM), which has a long half-life and was launched immediately before the first MRMP detection. Six strains isolated from Japanese children in 2019 and reference strain (FH), all belonging to the recent dominant P1 genotype, two, or two subtype, were cultivated in a medium containing slightly higher concentrations than the originated minimum inhibitory concentration (MIC) of AZM and underwent sequencing if they grew. Four out of the seven strains grew after exposure to AZM, and C2617G and C2617A were detected, with no mutation in two strains. After another cultivation and sequencing, two of four strains grew, one was changed from C2617G to A2063G, and the other remained C2617A. The MIC of AZM in A2063G strains was 128 mg/mL; for C2617A, it was 0.0156 mg/mL. This is the first study to detect the strains with A2063G mutation from recent macrolide-susceptible M. pneumoniae using AZM exposure.

30 September 2021 in Japanese Journal of Infectious Diseases
Verified
Journal Article
Closed access
PDF file
Tomohiro OishiTomohiro Oishi
Tomohiro Oishi
TMTetsuro Muratani
Tetsuro Muratani
TTTakaaki Tanaka
Takaaki Tanaka
MSMasahisa Sato
Masahisa Sato
KUKohdera Urara
Kohdera Urara
CNChikara Nakahama
Chikara Nakahama
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies